Winter Park, Florida--(Newsfile Corp. - May 20, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine, today announced that its subsidiary Adia Med of Winter Park LLC is now actively recruiting participants for two key clinical studies officially listed as "Recruiting" on ClinicalTrials.gov.

https://clinicaltrials.gov/study/NCT07572890#study-overview

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/298208_kidneystudy.jpg

Each study is enrolling up to 100 participants. The Kidney Health Study (NCT07572890 - Adia Med of Winter Park LLC Chronic Kidney Disease Research Study) and the Lower Back Pain Study (NCT07587047 - Adia Med of Winter Park LLC Lower Back Pain Research Study) are evaluating the safety and preliminary efficacy of AdiaVita™ - Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product - in adults with Stage 2-4 Chronic Kidney Disease and chronic lower back pain, respectively. Both studies include a patient-paid participation fee of $15,000 for the Kidney Health Study and $5,000 for the Lower Back Pain Study. These fees are designed to assist in offsetting the substantial costs associated with conducting the clinical trials. If both studies reach full enrollment, Adia Med anticipates receiving $1,500,000 from the Kidney Health Study and $500,000 from the Lower Back Pain Study, for a combined total of $2,000,000.

https://clinicaltrials.gov/study/NCT07587047?term=adia&viewType=Card&rank=4

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/298208_backstudy.jpg

Additionally, the Georgia Autism Study has already applied for approval and registration on ClinicalTrials.gov.

"Reaching the active recruitment phase for both the kidney and lower back pain studies listed on ClinicalTrials.gov is a major milestone for Adia Med and the patients we serve," said Larry Powalisz, CEO of Adia Nutrition Inc. "We are excited to open enrollment and begin collecting real-world clinical data on our regenerative therapies."

Interested individuals are encouraged to visit ClinicalTrials.gov and search for the study identifiers above or contact Adia Med directly to learn about eligibility, screening, and participation details.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298208